Takeda Pharmaceutical Company Limited (NYSE:TAK) Stock Position Decreased by Sanctuary Advisors LLC

Sanctuary Advisors LLC lessened its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 57.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,451 shares of the company's stock after selling 40,570 shares during the quarter. Sanctuary Advisors LLC's holdings in Takeda Pharmaceutical were worth $403,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Gold Investment Management Ltd. lifted its position in shares of Takeda Pharmaceutical by 2.0% during the 3rd quarter. Gold Investment Management Ltd. now owns 73,204 shares of the company's stock valued at $1,049,000 after acquiring an additional 1,428 shares during the period. Smithfield Trust Co increased its stake in Takeda Pharmaceutical by 76.9% in the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock valued at $49,000 after purchasing an additional 1,490 shares in the last quarter. Kovitz Investment Group Partners LLC raised its holdings in Takeda Pharmaceutical by 7.0% during the third quarter. Kovitz Investment Group Partners LLC now owns 25,456 shares of the company's stock worth $362,000 after purchasing an additional 1,670 shares during the last quarter. Aaron Wealth Advisors LLC raised its holdings in Takeda Pharmaceutical by 7.2% during the fourth quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company's stock worth $331,000 after purchasing an additional 1,670 shares during the last quarter. Finally, Versant Capital Management Inc purchased a new stake in Takeda Pharmaceutical during the fourth quarter worth $26,000. 9.17% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Takeda Pharmaceutical Price Performance

TAK traded up $0.19 during midday trading on Friday, reaching $15.19. 866,590 shares of the company's stock were exchanged, compared to its average volume of 1,797,626. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.22. The stock has a market capitalization of $48.32 billion, a PE ratio of 37.96, a P/E/G ratio of 0.24 and a beta of 0.46. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The business's 50-day moving average price is $13.55 and its 200 day moving average price is $13.91.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, equities analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.